Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. Among authors: amarenco p. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
High-dose atorvastatin after stroke or transient ischemic attack.
Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. Amarenco P, et al. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894. N Engl J Med. 2006. PMID: 16899775 Free article. Clinical Trial.
The paradox of cholesterol and stroke.
Amarenco P, Steg PG. Amarenco P, et al. Lancet. 2007 Dec 1;370(9602):1803-4. doi: 10.1016/S0140-6736(07)61751-6. Lancet. 2007. PMID: 18061038 No abstract available.
Lipoprotein(a) as a cardiovascular risk factor: current status.
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Nordestgaard BG, et al. Among authors: amarenco p. Eur Heart J. 2010 Dec;31(23):2844-53. doi: 10.1093/eurheartj/ehq386. Epub 2010 Oct 21. Eur Heart J. 2010. PMID: 20965889 Free PMC article.
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel. Chapman MJ, et al. Among authors: amarenco p. Eur Heart J. 2011 Jun;32(11):1345-61. doi: 10.1093/eurheartj/ehr112. Epub 2011 Apr 29. Eur Heart J. 2011. PMID: 21531743 Free PMC article. Review.
Overlap of diseases underlying ischemic stroke: the ASCOD phenotyping.
Sirimarco G, Lavallée PC, Labreuche J, Meseguer E, Cabrejo L, Guidoux C, Klein IF, Olivot JM, Abboud H, Adraï V, Kusmierek J, Ratani S, Touboul PJ, Mazighi M, Steg PG, Amarenco P. Sirimarco G, et al. Among authors: amarenco p. Stroke. 2013 Sep;44(9):2427-33. doi: 10.1161/STROKEAHA.113.001363. Epub 2013 Jul 16. Stroke. 2013. PMID: 23860300
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.
Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ. Boekholdt SM, et al. Among authors: amarenco p. Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21. Circulation. 2013. PMID: 23965489 Free PMC article.
Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Giugliano RP, et al. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251359 Free article. Clinical Trial.
Residual macrovascular risk in 2013: what have we learned?
Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM Jr, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoğlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P; Residual Risk Reduction Initiative (R3i). Fruchart JC, et al. Among authors: amarenco p. Cardiovasc Diabetol. 2014 Jan 24;13:26. doi: 10.1186/1475-2840-13-26. Cardiovasc Diabetol. 2014. PMID: 24460800 Free PMC article. Review.
477 results